| Description | TM-25659 is a modulator of transcriptional co-activator with PDZ-binding motif (TAZ), with anti-osteoporotic and anti-obesity activities. |
| In vitro | TM-25659（2, 10, 20, 100 µM）以剂量依赖性增强了TAZ在细胞核的定位，并通过促进TAZ对PPARγ的抑制作用，减缓了PPARγ介导的脂肪细胞分化。此外，TM-25659（2, 10, 50 µM）提升了成骨基因的表达，从而增加了成骨细胞的分化[1]。 |
| In vivo | 在体内，TM-25659（每隔一天给药，50 mg/kg，腹腔注射，持续2周）能够抑制骨质流失，并减少肥胖模型中的体重增加。TM-25659在静脉注射（i.v.）或口服（p.o.）后的血浆浓度随时间下降，半衰期大约为7小时或10小时，系统清除率（CL）为0.21 L/(h×kg)，而稳态分布容积（1.91 L/(h×kg)）则大于总体液体体积[1]。 |
| molecular weight | 500.6 |
| Molecular formula | C30H28N8 |
| CAS | 260553-97-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 100 mg/mL (199.8 mM) |
| References | 1. Jang EJ, et al. TM-25659 enhances osteogenic differentiation and suppresses adipogenic differentiation by modulating the transcriptional co-activator TAZ. Br J Pharmacol. 2012 Mar;165(5):1584-94. |